Table 3. Clinical and biochemical characteristics of subjects with GnRH agonist treatment according to BMI categories.
| Variable | Normal weight at baseline (n=60, 72.3%) | Overweight/obese at baseline (n=23, 27.7%) | ||||
|---|---|---|---|---|---|---|
| Baseline | 1 Year | P-value | Baseline | 1 Year | P-value | |
| Chronological age (yr) | 8.4±0.5 | 9.4±0.5 | <0.001 | 8.5±0.5 | 9.5±0.4 | <0.001 |
| Bone age (yr) | 10.0±0.8 | 10.6±0.8 | <0.001 | 10.5±0.6 | 11.2±0.7 | <0.001 |
| BA-CA (yr) | 1.6±0.7 | 1.2±0.8 | <0.001 | 1.9±0.7 | 1.7±0.8 | 0.008 |
| Height (cm) | 132.3±5.0 | 138.1±5.0 | <0.001 | 135.1±5.1 | 140.9±5.0 | <0.001 |
| Height z-score | 0.8±0.8 | 0.8±0.7 | 0.754 | 1.2±0.8 | 1.1±0.7 | 0.278 |
| Weight (kg) | 29.0±3.9 | 33.6±4.9 | <0.001 | 38.1±4.8 | 43.1±5.7 | <0.001 |
| Weight z-score | 0.4±0.7 | 0.5±0.7 | 0.001 | 1.6±0.4 | 1.6±0.5 | 0.657 |
| BMI (kg/m2) | 16.5±1.5 | 17.8±2.6 | <0.001 | 20.8±1.6 | 21.7±1.8 | 0.001 |
| BMI z-score | -0.1±0.7 | 0.1±0.8 | <0.001 | 1.5±0.4 | 1.5±0.4 | 0.779 |
| Waist circumference (cm) | 58.5±5.1 | 62.7±5.3 | <0.001 | 70.0±5.1 | 73.6±6.4 | 0.001 |
| Waist circumference to height ratio (%) | 44.2±3.1 | 45.4±3.3 | <0.001 | 51.9±3.5 | 52.2±4.2 | 0.580 |
| Overweight & obese, n (%) | 0 (0) | 7 (11.7) | 0.006 | 23 (100) | 20 (87.0) | <0.001 |
| Abdominal obesity, n (%) | 2 (1.7) | 2 (1.7) | 1.000 | 17 (73.9) | 16 (69.6) | 0.743 |
| Glucose (mg/dL) | 83.8±7.1 | 95.4±5.5 | <0.001 | 86.3±7.2 | 97.6±5.2 | <0.001 |
| Insulin (µIU/mL) | 8.7±4.2 | 7.4±3.5 | 0.031 | 10.2±4.9 | 11.4±3.9 | 0.348 |
| FGIR | 12.1±6.6 | 15.3±6.2 | 0.001 | 10.7±6.8 | 9.7±3.6 | 0.558 |
| QUICKI | 0.36±0.03 | 0.36±0.02 | 0.889 | 0.35±0.03 | 0.33±0.02 | 0.044 |
| HOMA-IR | 1.8±1.0 | 1.8±0.9 | 0.590 | 2.2±1.2 | 2.8±1.0 | 0.060 |
| GnRH agonist dose (µg/kg) | 73.6±11.6 | 60.1±14.8 | <0.001 | 66.5±6.8 | 57.1±12.6 | <0.001 |
Values are presented as mean±standard deviation or number (%).
GnRH, gonadotropin-releasing hormone; BMI, body mass index; BA-CA, bone age-chronological age; FGIR, fasting glucose to insulin ratio; QUICKI, quantitative insulin sensitivity check index; HOMA-IR; homeostasis model assessment of insulin resistance.